Toggle light / dark theme

Corstasis scores FDA nod for nasal spray treatment, touts sales potential

Forty-two years after approving the potent diuretic Bumex (bumetanide) as both an oral and infused treatment for edema, the FDA has endorsed a new version of the drug to be delivered as a nasal spr | Forty-two years after approving the potent diuretic Bumex (bumetanide) as both an oral and infused treatment for edema, the FDA has endorsed a new version of the drug to be delivered as a nasal spray. The U.S. regulator has signed off on Corstasis Therapeutics’ Enbumyst to relieve the edema associated with congestive heart failure, chronic kidney disease and liver disease.

Leave a Comment

Lifeboat Foundation respects your privacy! Your email address will not be published.

/* */